Tizanidine

Active ingredient: Tizanidine Hydrochloride

In short: Tizanidine is indicated for the treatment of spasticity in adults.

Forms & strengthsTablets Tizanidine tablets USP, 2 mg are white to off-white, round, flat, bevel edged uncoated tablets debossed with "U" and "168" on one side and bisecting score on other side. …
LabelPD-Rx Pharmaceuticals, Inc.
Label updatedNov 16, 2026

What is Tizanidine used for?

Tizanidine is indicated for the treatment of spasticity in adults.

Tizanidine dosage

Monitoring of aminotransferase levels is recommended at baseline and 1 month after maximum dose is achieved

.

The recommended starting dose is 2 mg by mouth every 6 to 8 hours, as needed, to a maximum of three doses in 24 hours.

Dosage can be gradually increased every 1 to 4 days by 2 mg to 4 mg at each dose based on clinical response and tolerability. The maximum total daily dosage is 36 mg. Single doses greater than 16 mg have not been studied.

There are pharmacokinetic differences when administering Tizanidine between the fed or fasted state

. Tizanidine may be taken with or without food; however, consistent administration with respect to food is recommended to reduce variability in tizanidine plasma exposure.

Because of the short duration of therapeutic effect, treatment with Tizanidine should be reserved for those daily activities and times when relief of spasticity is most important.

In patients with creatinine clearance < 25 mL/min, use lower individual doses during titration. If higher doses are required, the individual doses rather than dosing frequency should be increased

.

In patients with hepatic impairment, use lower individual doses during titration. If higher doses are required, individual doses rather than dosing frequency should be increased

.

When discontinuing Tizanidine, particularly in patients who have been receiving high doses for long periods or who may be on concomitant treatment with narcotics, decrease the dosage by 2 mg to 4 mg per day to minimize the risk of withdrawal adverse reactions

.

There are pharmacokinetic differences when:

1) switching between administration of Tizanidine with or without food

2) switching between dosage forms if being administered with food.

If these situations occur, monitor patients for therapeutic effect or adverse reactions

.

How to take Tizanidine — instructions & advice from the label

Serious Drug Interactions

Advise patients they should not take Tizanidine if they are taking fluvoxamine or ciprofloxacin because of the increased risk of serious adverse reactions including severe lowering of blood pressure and sedation. Instruct patients to inform their healthcare providers when they start or stop taking any medication because of the risks associated with interaction between Tizanidine and other medicines

.

Tizanidine Dosing and Administration

Tell patients to take Tizanidine exactly as prescribed (consistently either with or without food) and not to switch between tablets and capsules

. Inform patients that they should not take more Tizanidine than prescribed because of the risk of adverse events at single doses greater than 8 mg or total daily doses greater than 36 mg. Tell patients that they should not suddenly discontinue Tizanidine, because rebound hypertension and tachycardia may occur

.

Hypotension

Warn patients that they may experience hypotension and to be careful when changing from a lying or sitting to a standing position

. …

Warnings & precautions

Do not take this medicine if: Tizanidine is contraindicated in patients:

taking strong CYP1A2 inhibitors .

with a history of hypersensitivity to tizanidine or the ingredients in Tizanidine. Symptoms have included anaphylaxis and angioedema .

Tizanidine is an α2-adrenergic agonist that can produce hypotension

. Syncope has been reported in patients treated with tizanidine in the postmarketing setting. The risk of hypotension may be minimized by dose titration; monitoring for signs and symptoms of hypotension prior to dosage increase may minimize the risks associated with hypotension. In addition, patients moving from a supine to fixed upright position may be at increased risk for hypotension and orthostatic effects.

Monitor for hypotension when Tizanidine is used in patients receiving concurrent antihypertensive therapy. It is not recommended that Tizanidine be used with other α2-adrenergic agonists. Clinically significant hypotension (decreases in both systolic and diastolic pressure) has been reported with concomitant administration of tizanidine and strong CYP1A2 inhibitors

. Therefore, concomitant use of Tizanidine with strong CYP1A2 inhibitors is contraindicated

.

(

7.1)]

.

Tizanidine may cause hepatocellular liver injury. Liver function test abnormality and hepatotoxicity have been observed with Tizanidine

. Monitoring of aminotransferase levels is recommended at baseline and 1 month after maximum dose is achieved, or if hepatic injury is suspected

.

Tizanidine can cause sedation, which may interfere with everyday activity. In the multiple dose studies of Tizanidine, the prevalence of patients with sedation peaked following the first week of titration and then remained stable for the duration of the maintenance phase of the study

. …

Tizanidine side effects

The following clinically significant adverse reactions are described elsewhere in other sections of the prescribing information:

Hypotension

Liver Injury

Sedation

Hypersensitivity Reactions

Withdrawal Adverse Reactions

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.

The safety of Tizanidine has been evaluated in three double-blind, randomized, placebo-controlled clinical studies

. Two studies were conducted in patients with multiple sclerosis and one in patients with spinal cord injury. Each study had a 13-week active treatment period which included a 3-week titration phase to the maximum tolerated dose up to 36 mg/day in three divided doses, a 9-week plateau phase where the dose of tizanidine was held constant and a 1-week dose tapering period. In all, 264 patients received tizanidine and 261 patients received placebo. Across the three studies approximately 51% of patients were women, and the median dose during the plateau phase ranged from 20 to 28 mg/day.

The most common adverse reactions (>10% of patients treated with Tizanidine) reported in multiple dose, placebo-controlled clinical studies involving 264 patients with spasticity were dry mouth, somnolence/sedation, asthenia (weakness, fatigue and/or tiredness), and dizziness. …

Drug interactions

Concomitant use of Tizanidine with strong cytochrome P450 1A2 (CYP1A2) inhibitors (e.g., fluvoxamine, ciprofloxacin) is contraindicated. Changes in pharmacokinetics of tizanidine when administered with a strong CYP1A2 inhibitor resulted in significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment

.

Concomitant use of Tizanidine with moderate or weak CYP1A2 inhibitors (e.g., zileuton, antiarrhythmics [amiodarone, mexiletine, propafenone, and verapamil], cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided. If concomitant use is clinically necessary, and adverse reactions such as hypotension, bradycardia, or excessive drowsiness occur, reduce Tizanidine dosage or discontinue Tizanidine therapy

.

Concomitant use of Tizanidine with oral contraceptives is not recommended. However, if concomitant use is clinically necessary and adverse reactions such as hypotension, bradycardia, or excessive drowsiness occur, reduce or discontinue Tizanidine therapy.

Alcohol increases the exposure of tizanidine after administration of Tizanidine. This was associated with an increase in adverse reactions of Tizanidine. …

About this medicine

Tizanidine Tablets contains tizanidine hydrochloride as the active ingredient, which is a central alpha

2-adrenergic agonist. Its chemical name is 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3- benzothiadiazole monohydrochloride. It has a molecular formula of C

9H

8ClN

5S-HCl and a molecular weight of 290.2. Its structural formula is:

Tizanidine hydrochloride is a white to off-white, fine crystalline powder, which is odorless or with a faint characteristic odor. Tizanidine hydrochloride is slightly soluble in water and methanol; solubility in water decreases as the pH increases

Tizanidine tablets, are for oral administration and contain 2 or 4 mg tizanidine (equivalent to 2.288 mg and 4.576 mg tizanidine hydrochloride, respectively), and the inactive ingredients anhydrous lactose, colloidal silicon dioxide, microcrystalline cellulose, and stearic acid.

How it works: Tizanidine is a central alpha-2-adrenergic receptor agonist and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine are greatest on polysynaptic pathways. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 615dfd5c-125a-40e2-a6da-afacde305282. Read the full official label on DailyMed.